The curative effect analysis of radiation combined with targeted therapy of EGFR-TKI in patients with stage IV NSCLC
10.3760/cma.j.issn.1008-6315.2011.07.026
- VernacularTitle:晚期非小细胞肺癌放射治疗联合靶向治疗效果分析
- Author:
Lixin DONG
;
Wenjun LI
;
Shufen DONG
;
Zhanzhao FU
;
Ping LI
;
Qinghuai ZHANG
;
Tao GU
;
Sen YANG
;
Shaorong ZHANG
- Publication Type:Journal Article
- Keywords:
Non-smal cell lung cancer;
Radiotherapy;
Targeted therapy;
EGFR
- From:
Clinical Medicine of China
2011;27(7):744-746
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of radiation combined with targeted therapy of EGFR-TKI in the patients with stage IV non-small cell lung cancer ( NSCLC). Methods There were 17 female and 9 male patients with NSCLC enrolled into this study, which included 19 adenocarcinoma, 4 alveolar carcinoma and 3 uncertain carcinoma according to the iconography findings. Sixteen patients suffered from single or multiple bone metastasis,and 10 cases with brain metastasis. Gefitinib 250 mg or Erlotinib ISO mg per day were administrated during and after the process of radiation until the disease progressed. Results All patients had complete combined therapy, 12 of them suffered from diarrhea, 8 from emesia and 12 from erythra. The average score of ECOG improved from 3 to 2 after combined therapy. The bone metastasis control rate was 93.8% ,brain metastasis control rate was 70.0% , and the 6-month local lung lumps control rate was 84. 6%. Conclusion Palliative radiation combined with targeted therapy of EGFR-TKI is an effect and safe therapy for the patients with the stage IV of NSCLC, but the influence on survival shall be observed in further study.
